Stifel lowered the firm’s price target on RxSight (RXST) to $9 from $17 and keeps a Hold rating on the shares. The firm’s Light Adjustable Lens consignment inventory analysis shows normal customer inventory levels at the end of 1Q25, despite unexpected March LAL softness, the analyst tells investors in a research note.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RXST:
- RxSight downgraded to Neutral from Buy at BTIG
- RxSight’s Strategic Initiatives and International Expansion Support Buy Rating Amidst Revenue Challenges
- RxSight downgraded to Equal Weight from Overweight at Wells Fargo
- Closing Bell Movers: AES Corp jumps 14% on takeover possibility
- RxSight cuts FY25 revenue view to $120M-$130M from $160M-$175M